We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
Cap. Flow
-$1.39B
Cap. Flow %
-6.39%
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$166M
2
ROIV icon
Roivant Sciences
ROIV
+$137M
3
IMVT icon
Immunovant
IMVT
+$130M
4
BBIO icon
BridgeBio Pharma
BBIO
+$96.5M
5
BIDU icon
Baidu
BIDU
+$94.1M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$498M
2
AMZN icon
Amazon
AMZN
+$398M
3
SCHW
Charles Schwab
SCHW
+$372M
4
AON icon
Aon
AON
+$365M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$286M

Sector Composition

Rank Sector Weight
1 Healthcare 54.84%
2 Communication Services 8.41%
3 Technology 5.7%
4 Financials 3.99%
5 Consumer Discretionary 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
51
Abivax
ABVX
$10B
$16.3M 0.08%
122,000
+120,000
+6,000% +$13.6M
VNET
52
VNET Group
VNET
$1.91B
$16M 0.07%
1,992,000
+1,368,653
+220% +$12.4M
NTES icon
53
NetEase
NTES
$82.1B
$15.8M 0.07%
123,500
-167,719
-58% -$19.8M
BIIB icon
54
Biogen
BIIB
$32B
$15.3M 0.07%
+71,000
New +$13.6M
TSHA icon
55
Taysha Gene Therapies
TSHA
$1.98B
$15.3M 0.07%
+2,250,000
New +$13.3M
MOBI
56
Mobia Medical
MOBI
$353M
$15.1M 0.07%
+1,128,557
New +$14.6M
NERV icon
57
Minerva Neurosciences
NERV
$231M
$13.1M 0.06%
2,365,000
– –
ALMR
58
Alamar Biosciences
ALMR
$2.38B
$12.5M 0.06%
+462,900
New +$10.5M
ALVO icon
59
Alvotech
ALVO
$1.5B
$10.6M 0.05%
2,859,675
+2,660,000
+1,332% +$9.51M
BBNX
60
Beta Bionics
BBNX
$857M
$9.32M 0.04%
595,000
-3,012,920
-84% -$35.8M
IFRX icon
61
InflaRx
IFRX
$309M
$7.45M 0.03%
+3,325,000
New +$6.25M
SMG icon
62
ScottsMiracle-Gro
SMG
$3.55B
$5.99M 0.03%
+88,000
New +$5.45M
WAY
63
Waystar Holding Corp
WAY
$4.8B
$5.44M 0.03%
+264,900
New +$5.57M
BC icon
64
Brunswick
BC
$5.24B
$5.14M 0.02%
+61,000
New +$4.89M
GNTX icon
65
Gentex
GNTX
$4.98B
$5.03M 0.02%
+199,000
New +$4.71M
IDXX icon
66
Idexx Laboratories
IDXX
$43.9B
$4.74M 0.02%
+9,000
New +$5.05M
PRME icon
67
Prime Medicine
PRME
$615M
$4.58M 0.02%
1,240,843
– –
CMC icon
68
Commercial Metals
CMC
$7.34B
$4.2M 0.02%
+67,000
New +$4.71M
JATT
69
JATT II Acquisition Corp
JATT
$103M
$3.41M 0.02%
+300,000
New +$3.19M
SGMT icon
70
Sagimet Biosciences
SGMT
$637M
$3.21M 0.01%
+415,000
New +$2.82M
SMC
71
Summit Midstream
SMC
$470M
$1.66M 0.01%
58,214
– –
TEVA icon
72
Teva Pharmaceuticals
TEVA
$43.5B
$1.36M 0.01%
40,000
-314,000
-89% -$10.5M
RVMDW icon
73
Revolution Medicines Inc Warrant
RVMDW
$130M
$1.13M 0.01%
120,085
– –
COGT icon
74
Cogent Biosciences
COGT
$6.37B
$658K ﹤0.01%
17,000
– –
ANNAW
75
AleAnna Inc Warrant
ANNAW
$7.3M
$297K ﹤0.01%
990,000
– –
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2026 Portfolio in Review

As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Thomas Steyer withdrew a net $1.39B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.

  • Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
  • Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
  • Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
  • Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
  • Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
  • Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
  • Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.